The Emirates Health Services Corporation has made a significant breakthrough by introducing the innovative long-acting medication “BYANNLI” for schizophrenia patients at the Hope Mental Health Hospital. This marks the first instance of a government hospital in the UAE adopting this advanced treatment developed by Johnson & Johnson.
Advancements in Schizophrenia Treatment
BYANNLI is noted for its long-acting formulation, allowing for a single dose to be administered every six months. This development represents one of the latest advancements in managing schizophrenia, a complex and chronic mental disorder that can severely impact the lives of patients and their families if not managed effectively.
Commitment to Modern Healthcare
Dr. Essam Al Zarouni, the Executive Director of the Medical Services Sector at the Emirates Health Services Corporation, emphasized that the inclusion of this innovative treatment reflects the institution’s ongoing commitment to providing the latest globally approved therapeutic options. “This step signifies a qualitative leap in mental healthcare, enhancing the patient experience and enabling more sustainable and effective care,” he stated. He added that such advancements align with the institution’s goal of developing comprehensive care models focused on patient needs, quality of life, and long-term health outcomes.
Addressing Long-term Treatment Challenges
Dr. Noor Al Mehairi, Director of the Mental Health Department at the Emirates Health Services Corporation, pointed out that continuity of treatment is a significant challenge in chronic mental illnesses. She noted that the availability of BYANNLI offers a sophisticated option that aids in adhering to treatment plans, reducing the risk of relapse, and achieving higher levels of psychological and social stability for patients. “The more we succeed in supporting consistent treatment and regular follow-ups, the better it reflects on the patient, their families, and caregivers,” she remarked, underlining the importance of this medication in the evolving mental health system.
Global Trends and Health Resource Efficiency
This new treatment aligns with global developments in mental health, designed to promote sustainable symptom control and reduce the frequency of required doses. Such innovations not only enhance treatment compliance and efficacy but also improve the efficiency of health resource usage and care outcomes.
The Impact of Long-acting Treatments
The Hope Mental Health Hospital has reported outstanding results in applying long-acting treatments for patients dealing with chronic mental disorders. The introduction of these treatments has led to a decrease in patient readmission rates to less than 1%, as well as an impressive 93% adherence rate to treatment plans. Furthermore, 93% of patients have shown marked improvement in their psychological symptoms, reflecting the high quality of care provided and the effectiveness of the treatment models in practice.
Supporting a Vision for Integrated Health Services
By integrating this innovative treatment into the public health sector, the Emirates Health Services Corporation continues to uphold its approach of delivering proactive and comprehensive health services centred on innovation and quality. This initiative not only promotes community health but also supports the UAE’s vision of establishing a world-class healthcare system.
A transformative step towards sustaining mental healthcare, family stability, and enhancing the quality of life for patients.
Implementation of long-acting treatments has contributed to lowering readmission rates to under 1%.